MA3-002

BCAP31 antibody from Invitrogen Antibodies

6C6-Ag, BAP31, CDM, DXS1357E

Western blot: Supportive data in Antibodypedia

ELISA: Recommended by provider

Immunocytochemistry: Supportive data in Antibodypedia

Immunoprecipitation: Recommended by provider

Immunohistochemistry: Supportive data in Antibodypedia

Other assay: Supportive data in Antibodypedia

Provider product page for MA3-002

Antibody data

Antibody Data
References [10]
Comments [0]
Validations
Western blot [8]
Immunocytochemistry [7]
Immunohistochemistry [2]
Other assay [10]

Submit

Product number: MA3-002
Provider: Invitrogen Antibodies
Product name: BAP31 Monoclonal Antibody (CC-1)
Provider product page: Invitrogen Antibodies - MA3-002
Antibody type: Monoclonal
Antigen: Other
Description: Applications Tested: This eBio124-1D1 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Reactivity: Human, Mouse, Bovine, Hamster
Host: Rat
Isotype: IgG
Antibody clone number: CC-1
Vial size: 100 µL
Concentration: Conc. Not Determined
Storage: -20° C, Avoid Freeze/Thaw Cycles

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of BAP31 using a monoclonal antibody (Product # MA3-002).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of BAP31 was achieved by transfecting HeLa cells with BAP31 specific siRNAs (Silencer® select Product # s19721, s19722). Western blot analysis (Fig. a) was performed using whole cell extracts from the BAP31 knockdown cells (lane 3), non-specific scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blot was probed with BAP31 Monoclonal Antibody (Product # MA3-002, 1:1000 dilution) and F(ab')2- Rabbit anti-Rat IgG (H+L) Secondary Antibody, HRP conjugate (Product # PA1-29927, 0.25µg/ml, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig. b). Decrease in signal upon siRNA mediated knock down confirms that antibody is specific to BAP31.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell extract (30 µg lysate) of MCF7 (Lane 1), U937 (Lane 2), HepG2 (Lane 3), SHSY5Y (Lane 4) and Raji (Lane 5). The blot was probed with Anti-BAP31 Monoclonal Antibody (CC-1) (Product # MA3-002, 1:1000 dilution) and detected by chemiluminescence using Goat anti-Rat IgG (H+L) Secondary Antibody, HRP conjugate (Product # 31470, 0.25 µg/ml, 1:4000 dilution). A 28 kDa band corresponding to BAP31 was observed in all cell lines.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of BAP31 was achieved by transfecting HeLa cells with BAP31 specific siRNAs (Silencer® select Product # s19721, s19722). Western blot analysis (Fig. a) was performed using whole cell extracts from the BAP31 knockdown cells (lane 3), non-specific scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blot was probed with BAP31 Monoclonal Antibody (Product # MA3-002, 1:1000 dilution) and F(ab')2- Rabbit anti-Rat IgG (H+L) Secondary Antibody, HRP conjugate (Product # PA1-29927, 0.25µg/ml, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig. b). Decrease in signal upon siRNA mediated knock down confirms that antibody is specific to BAP31.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of BAP31 using a monoclonal antibody (Product # MA3-002).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of BAP31 was achieved by transfecting HeLa cells with BAP31 specific siRNAs (Silencer® select Product # s19721, s19722). Western blot analysis (Fig. a) was performed using whole cell extracts from the BAP31 knockdown cells (lane 3), non-specific scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blot was probed with BAP31 Monoclonal Antibody (Product # MA3-002, 1:1000 dilution) and F(ab')2- Rabbit anti-Rat IgG (H+L) Secondary Antibody, HRP conjugate (Product # PA1-29927, 0.25µg/ml, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig. b). Decrease in signal upon siRNA mediated knock down confirms that antibody is specific to BAP31.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell extract (30 µg lysate) of MCF7 (Lane 1), U937 (Lane 2), HepG2 (Lane 3), SHSY5Y (Lane 4) and Raji (Lane 5). The blot was probed with Anti-BAP31 Monoclonal Antibody (CC-1) (Product # MA3-002, 1:1000 dilution) and detected by chemiluminescence using Goat anti-Rat IgG (H+L) Secondary Antibody, HRP conjugate (Product # 31470, 0.25 µg/ml, 1:4000 dilution). A 28 kDa band corresponding to BAP31 was observed in all cell lines.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of BAP31 was achieved by transfecting HeLa cells with BAP31 specific siRNAs (Silencer® select Product # s19721, s19722). Western blot analysis (Fig. a) was performed using whole cell extracts from the BAP31 knockdown cells (lane 3), non-specific scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blot was probed with BAP31 Monoclonal Antibody (Product # MA3-002, 1:1000 dilution) and F(ab')2- Rabbit anti-Rat IgG (H+L) Secondary Antibody, HRP conjugate (Product # PA1-29927, 0.25µg/ml, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig. b). Decrease in signal upon siRNA mediated knock down confirms that antibody is specific to BAP31.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of BAP31 (green) showing staining in the cytoplasm of Hela cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a BAP31 monoclonal antibody (Product # MA3-002) in 3% BSA-PBS at a dilution of 1:200 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with Hoechst or DAPI (blue). Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of BAP31 (green) showing staining in the cytoplasm of MCF-7 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a BAP31 monoclonal antibody (Product # MA3-002) in 3% BSA-PBS at a dilution of 1:200 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with Hoechst or DAPI (blue). Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of BAP31 (green) showing staining in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a BAP31 monoclonal antibody (Product # MA3-002) in 3% BSA-PBS at a dilution of 1:200 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with Hoechst or DAPI (blue). Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of BAP31 (green) showing staining in the cytoplasm of Hela cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a BAP31 monoclonal antibody (Product # MA3-002) in 3% BSA-PBS at a dilution of 1:200 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with Hoechst or DAPI (blue). Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of BAP31 (green) showing staining in the cytoplasm of MCF-7 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a BAP31 monoclonal antibody (Product # MA3-002) in 3% BSA-PBS at a dilution of 1:200 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with Hoechst or DAPI (blue). Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of BAP31 (green) showing staining in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a BAP31 monoclonal antibody (Product # MA3-002) in 3% BSA-PBS at a dilution of 1:200 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with Hoechst or DAPI (blue). Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of BAP31 was performed using 70% confluent log phase HeLa cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with BAP31 Monoclonal Antibody (Product # MA3-002) at 1:200 dilution in 0.1% BSA, incubated at 4 degree Celsius overnight and then labeled with Goat anti-Rat IgG (H+L) Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A-11006) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing localization in endoplasmic reticulum, golgi and mitochondria. Panel e represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 3 Hsp105 is indispensable for SV40 cytosol arrival. A . CV-1 cells transfected with the indicated siRNAs for 24 h were incubated with SV40 (MOI ~5), harvested 12 hpi, and processed according to the semi-permeabilized cytosol arrival assay (see Methods ). Hsp90 and PDI serve as markers for the cytosol and membrane fraction, respectively. B . Relative VP1 band intensities in the cytosol fraction in (A) were quantified. Data are normalized to ctrl siRNA. Values represent the mean +- SD (n = 3). C . Membrane fraction in (A) was solubilized in a buffer containing 1% Triton X-100. After centrifugation, the extracted material containing ER-localized SV40 was analyzed by immunoblotting with VP1 antibodies (top panel). Relative VP1 band intensities in the ER-localized fraction were quantified as in (B) (bottom panel). D . As in (A), except cells were treated with 10 nM cholera toxin for 90 min before harvesting and analyzing using the indicated antibodies. E . CV-1 cells were transfected with either ctrl or Hsp105 siRNA #1. After 24 h, cells were infected with SV40 (MOI ~20) for 16 h. Cells were then fixed, stained, and analyzed by immunofluorescence microscopy. The experimental set-up is depicted on the left side of the figure. The insert shows a 2x enlarged area of the dotted box. Scale bar, 20 mum. F . The siRNA-transfected cells were scored for the presence of at least one BAP31-positive focus in each cell, and the values normalized to the ctrl siRNA. The bar graphs represent

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 4 Hsp105 overexpression enhances SV40 extraction into the cytosol. A . COS-7 cells expressing the indicated S-tagged construct were infected with SV40 (MOI ~5). 12 hpi, cells were processed as in Fig 3A , and the samples immunoblotted using the indicated antibodies. B . VP1 band intensities of the cytosol-localized SV40 in (A) were quantified and normalized against the Hsp90 band intensity. Values represent the mean +- SD (n>=3). * p =3). D . CV-1 cells expressing GFP-S or Hsp105 WT-S were infected with SV40 (MOI ~30) for 16 h. Cells were fixed, stained with BAP31 and VP1 antibodies, and imaged as in Fig 3E . The experimental set-up is depicted on the left side of the figure. In the first column, a representative cell expressing GFP-S (top row) or Hsp105 WT-S (second row) amongst cells not expressing this protein is shown. The insert shows a 2x enlarged area of the dotted box. Scale bar, 20 mum. E . Cells expressing the indicated tagged construct are scored for the presence of at least one BAP31-positive focus in each cell, and the values normalized to GFP. The bar graphs represent mean values +- SD (n>=3). F . Cells transfected with either ctrl or Hsp105 siRNA #1 were subsequently transfected with the indicated tagged construct, and BAP31 foci were quantified as in (E)

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. RTN3 and RTN4 are recruited to viral foci to enable SV40 engagement with the cytosolic extraction machinery. (a) CV-1 cells uninfected or infected with SV40 for 16 h were fixed, stained with the indicated antibodies, and processed by epifluorescence microscopy. (b) Quantification of the percentage of RTN3/RTN4 double-positive foci colocalizing with BAP31 foci. Values represent means +- SD from three independent experiments. (c) Quantification of the percentage of RTN3/RTN4 double knockdown cells harboring BAP31 foci after SV40 infection. Cells were scored positive if at least one focus was present in the cell. Values represent means +- SD from three independent experiments. (d and e) COS-7 cells were treated with the indicated siRNAs for 24 h, followed by transfection of the SGTA-S (d) or Hsc70-S (e) construct. After 24 h, cells were infected with SV40 for 16 h, and the resulting cell extracts were subjected to affinity purification (AP), SDS-PAGE, and immunoblotting with the indicated antibodies. Input represents 5% of the total sample used for the affinity purification. (f and g) The VP1 band intensities from d and e were quantified with ImageJ software, normalized relative to the precipitated SGTA-S or Hsc70-S level, and expressed as a percentage of the VP1 band intensity in the scrambled siRNA-treated sample. The graph represents the means and SDs from three independent experiments. Student's two-tailed t test was used to determine statistical significance. (h)

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. The SV40-induced ER focus is constructed proximal to Golgi-associated BICD2. (A) Confocal analysis of CV-1 cells that were infected with SV40 (MOI ~5) for 16 h and stained with anti-VP2/3 (green) and anti-BICD2 (red) antibodies. Cells were counterstained with DAPI (blue). Percentage represents the number of VP2/3 foci surrounded by BICD2 out of total cells with VP2/3 foci. (B) Confocal analysis of uninfected or SV40-infected cells (MOI ~5) stained with anti-BAP31 (green) and anti-BICD2 (red) antibodies. Cells were counterstained with DAPI (blue). Percentage represents the number of BAP31 foci surrounded by BICD2 out of total cells with virus-induced BAP31 foci. (C) Confocal analysis of control and BICD2-depleted CV-1 cells infected with SV40 (MOI ~5). At 16 hpi, cells were stained with anti-VP2/3 (green) and anti-BAP31 (red) and counterstained with DAPI (blue). The graph represents the percentage of cells with BAP31 + foci normalized to the scrambled control. (D) As in B, except cells were stained with anti-gamma-tubulin (white, arrows), anti-BICD2 (red), and anti-VP2/3 (green) antibodies. Cells were counterstained with DAPI (blue). (E) As in B, except cells were stained with anti-GM130 (green) and anti-BICD2 (red) antibodies. Cells were counterstained with DAPI (blue). Scale bars, 10 um. Values are averages of the means ( n = 3) +- SD. A standard Student's t test was used to determine statistical significance. See also Fig. S4 .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7. BICD2 localization to the Golgi is crucial to promote SV40 disassembly and infection. (A) CV-1 cells were transfected with either the mCitN 1 control or Rn KIF5C(1-560)-mCit-GTS construct for 24 h and stained for BICD2 (red/white). Cells were counterstained with DAPI (blue). (B) COS-7 cells were transfected with either the mCitN 1 control or Rn KIF5C(1-560)-mCit-GTS construct for 24 h. Cells were harvested and the BICD2 levels assessed by immunoblotting. Hsp90 was used as a loading control. Anti-GFP was used to detect mCit levels. The BICD2 band intensities in cells expressing mCitN 1 or Rn KIF5C(1-560)-mCit-GTS are quantified in graph below. (C) CV-1 cells were transfected with either the mCitN 1 control or Rn KIF5C(1-560)-mCit-GTS construct for 24 h and infected with SV40 (MOI~1). At 24 hpi, cells were fixed and stained for TAg. Only mCit expressing cells were counted (green). (D) As in C, except cells were infected for 16 h and stained with anti-VP2/3 (red), anti-BAP31 (pink) and counterstained with DAPI (blue). Data on graph was normalized to the mCitN 1 control. (E) COS-7 cells were transfected with either the mCitN 1 control or Rn KIF5C(1-560)-mCit-GTS construct for 24 h and then infected with SV40 (MOI~5). At 12 hpi, the cytosolic fraction was isolated and VP1 levels assessed by immunoblotting. Cytosolic Hsp90 was used as a loading control. The VP1 band intensities are quantified in the graph below. (F) As in E, except at 12 hpi, the cytosolic fraction was la

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure S4. The SV40-induced ER focus is surrounded by BICD2 and BICDR1 (related to Fig. 6 ). (A) Confocal analysis of CV-1 cells that were infected with SV40 (MOI ~5) for 16 h and stained with anti-VP1 (green) and anti-BICD2 (red) antibodies. Cells were counterstained with DAPI (blue). (B) Confocal analysis of uninfected and SV40-infected cells (MOI ~5) stained with anti-VP2/3 (pink), anti-BAP31 (green), and anti-BICD2 (red) antibodies. Cells were counterstained with DAPI (blue). (C) Confocal analysis of control and BICDR1-depleted CV-1 cells infected with SV40 (MOI ~5). At 16 hpi, cells were stained with anti-VP2/3 (green), anti-BAP31 (red), and counterstained with DAPI (blue). The graph represents the percentage of cells with BAP31 + foci normalized to the scrambled control. (D) As in A, except stained with anti-GM130 (green) and anti-BICDR1 (red) antibodies. Cells were counterstained with DAPI (blue). Scale bars, 10 um. Values are averages of the means ( n = 3) +- SD. A standard Student's t test was used to determine statistical significance.